Details

Autor(en) / Beteiligte

• Thera, Mahamadou A
• Doumbo, Ogobara K
• Coulibaly, Drissa
• Laurens, Matthew B
• Ouattara, Amed
• Kone, Abdoulaye K
• Guindo, Ando B
• Traore, Karim
• Traore, Idrissa
• Kouriba, Bourema
• Diallo, Dapa A
• Diarra, Issa
• Daou, Modibo
• Dolo, Amagana
• Tolo, Youssouf
• Sissoko, Mady
• Sissoko, Mahamadou S
• Niangaly, Amadou
• Takala-Harrison, Shannon
• Lyke, Kirsten E
• Wu, Yukun
• Blackwelder, William C
• Godeaux, Olivier
• Vekemans, Johan
• Dubois, Marie-Claude
• Ballou, W. Ripley
• Cohen, Joe
• Thompson, Darby
• Dube, Tina
• Soisson, Lorraine
• Diggs, Carter L
• House, Brent
• Lanar, David E
• Dutta, Sheetij
• Heppner, D. Gray
• Plowe, Christopher V

Titel

A Field Trial to Assess a Blood-Stage Malaria Vaccine

Ist Teil von

• The New England journal of medicine, 2011-09, Vol.365 (11), p.1004-1013

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In this study of 400 children in Mali, an adjuvanted vaccine based on an apical membrane antigen 1 from the 3D7 strain of Plasmodium falciparum (a blood-stage antigen) showed some strain-specific activity in preventing clinical malaria. An effective malaria vaccine would improve the prospects for eradicating malaria. 1 Vaccines that interrupt the transmission of malaria are emphasized in discussions of eradication, 2 but the ideal malaria vaccine would provide a direct clinical benefit. Vaccines targeting the blood stages of malaria are intended to reduce morbidity and mortality and are being developed in hopes of creating a multistage, multiantigen vaccine. 3 Vaccines based on two polymorphic Plasmodium falciparum blood-stage proteins, merozoite surface protein 1 4 and apical membrane antigen 1 (AMA1), 5 were not shown to be effective in recent studies, probably because of insufficient cross-protection against diverse malaria strains 6 , 7 or . . .